KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Passes Above Fifty Day Moving Average – Time to Sell?

Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) passed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $22.99 and traded as high as $26.96. KalVista Pharmaceuticals shares last traded at $26.9450, with a volume of 6,431,370 shares.

Analyst Ratings Changes

Several analysts have issued reports on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC downgraded KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. JonesTrading downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright downgraded KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their price target for the stock from $37.00 to $27.00 in a report on Friday, May 1st. Finally, Leerink Partners downgraded KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Three equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $30.60.

KalVista Pharmaceuticals Price Performance

The company has a market cap of $1.43 billion, a PE ratio of -7.79 and a beta of -0.12. The company has a debt-to-equity ratio of 8.18, a quick ratio of 5.10 and a current ratio of 5.17. The stock has a 50 day moving average of $22.99 and a 200-day moving average of $18.18.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The business had revenue of $40.86 million during the quarter, compared to analyst estimates of $39.03 million. Equities analysts predict that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Insider Transactions at KalVista Pharmaceuticals

In other news, insider Paul K. Audhya sold 2,239 shares of the business’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $26.78, for a total transaction of $59,960.42. Following the transaction, the insider directly owned 150,260 shares in the company, valued at $4,023,962.80. The trade was a 1.47% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Nicole Sweeny sold 1,489 shares of KalVista Pharmaceuticals stock in a transaction that occurred on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the insider directly owned 59,291 shares in the company, valued at approximately $1,587,812.98. The trade was a 2.45% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 261,295 shares of company stock valued at $4,764,294. 4.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Tudor Investment Corp ET AL acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $24,360,000. Jefferies Financial Group Inc. acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $3,494,000. Blue Owl Capital Holdings LP acquired a new position in shares of KalVista Pharmaceuticals during the third quarter worth $1,522,000. Hennion & Walsh Asset Management Inc. boosted its stake in KalVista Pharmaceuticals by 93.6% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after acquiring an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ boosted its stake in KalVista Pharmaceuticals by 391.9% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after acquiring an additional 160,128 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.